INTERVERTEBRAL FUSION DEVICE WITH BONE GRAFT,
Report
- Report Number
- 1030489-2018-01495
- Event Type
- Injury
- Date Received
- November 16, 2018
- Date of Event
- October 1, 2018
- Report Date
- November 13, 2024
- Manufacturer
- MEDTRONIC SOFAMOR DANEK
- Product Code
- MAX
- PMA / PMN Number
- SEE H10
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- FL, US
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
ADDITIONAL INFORMATION: B5 MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.
UPDATE RECEIVED ON 18 OCTOBER 2024: ONSET DATE: (B)(6) 2018 AND STILL ONGOING AT STUDY EXIT. THE EVENT IS ASSESSED AS POSSIBLE RELATED TO THE PLF GRAFTING MATERIAL, TO THE POSTERIOR FIXATION AND TO THE INTERBODYFUSION DEVICE BY THE SPONSOR ONLY.
THE FOLLOWING PRODUCTS WERE USED IN THE SURGERY: 1) PRODUCT ID: 6661036, LOT#: 0569184W, 510(K): K172199, UDI: (B)(4), PRODUCT CODE: MAX, QTY: 1. 2) PRODUCT ID: 6661136, LOT#: 0591366W, 510(K): K172199, UDI: (B)(4), PRODUCT CODE: MAX, QTY: 1. 3) PRODUCT ID: 54840006550, LOT#: H5337223, 510(K): K091974, UDI: (B)(4), PRODUCT CODE: NKB, QTY: 1. 4) PRODUCT ID: 54840006540, LOT#: H5307510, 510(K): K091974, UDI: (B)(4), PRODUCT CODE: NKB, QTY: 1. 5) PRODUCT ID: 5440030, LOT#: H5351674, 510(K): K102555, UDI: (B)(4), PRODUCT CODE: NKB, QTY: 1. ALTHOUGH IT IS UNKNOWN IF ANY OF THE DEVICES CONTRIBUTED TO THE REPORTED EVENT, WE ARE FILING THIS MDR FOR NOTIFICATION PURPOSES. NEITHER THE DEVICE NOR FILMS OF APPLICABLE IMAGING STUDIES WERE RETURNED TO THE MANUFACTURER FOR EVALUATION. THEREFORE, WE ARE UNABLE TO DETERMINE THE DEFINITIVE CAUSE OF THE REPORTED EVENT. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
PRE-OP DIAGNOSIS: INSTABILITY (UP TO AND INCLUDING GRADE 2 SPONDYLOLITHESIS, RETROLISTHESIS OR LATERAL LISTHESIS) NO. OF LEVELS TREATED: 2 IT WAS REPORTED THAT THE PATIENT UNDERWENT A SURGERY. POST-OP, ON (B)(6) 2018, THE PATIENT EXPERIENCED INCREASED RIGHT LEG PAIN THAT RADIATED INTO THE LATERAL THIGH. INVESTIGATION NOTED THE EVENT TO BE NON-SERIOUS. THE INVESTIGATOR DETERMINED THE ADVERSE EVENT TO BE POSSIBLY RELATED TO SURGICAL PROCEDURE, INTERBODY DEVICE, MULTIAXIAL SCREWS, RODS AND SET SCREWS. THE OUTCOME OF THE ADVERSE EVENT WAS PENDING.
ACCORDING TO THE SPONSOR ASSESSMENT, THE ADVERSE EVENT WAS NOTED TO BE POSSIBLY RELATED TO INTERBODY DEVICE, MULTI-AXIAL SCREWS, RODS AND SCREWS. NO RELATEDNESS WITH THE SURGICAL PROCEDURE WAS FOUND. THE PATIENT ALSO UNDERWENT AN ADDITIONAL SURGERY ON (B)(6) 2019. ANTERIOR LUMBAR INTERBODY FUSION WAS PERFORMED AT L2-L3 VIA TRANS PSOAS LEFT-SIDED APPROACH. ATTACHMENT WAS MADE TO PRIOR L3-L5 CONSTRUCT.
THE OUTCOME OF THE ADVERSE EVENT WAS RESOLVED ON (B)(6) 2019. ACCORDING TO THE SPONSOR ASSESSMENT, THE ADVERSE EVENT WAS CONSIDERED AS NON-SERIOUS.
RELATEDNESS OF THE ADDITIONAL SURGICAL PROCEDURE TO SURGICAL CONSTRUCT AND/OR THE STUDY PROCEDURE: NOT RELATED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 917304 | INTERVERTEBRAL FUSION DEVICE WITH BONE GRAFT, | MAX | MEDTRONIC SOFAMOR DANEK | NA | SEE H10 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | NA | Female | Other |